Table 4.
Association of CYP1A1*2C polymorphism with therapeutic response in CML patients
| Imatinib treatment response | Total n=95 n (%) | Total n=37 n (%) AA | Total n=57 n (%) AG | Total n=1 n (%) GG | P value |
|---|---|---|---|---|---|
| i. Hematological response | |||||
| Major (MHR) | 70 (74) | 23 (33) | 47 (67) | - | 0.03* |
| Minor (mHR) | 12 (13) | 6 (50) | 6 (50) | - | 0.42 |
| Poor (PHR) | 13 (14) | 8 (62) | 4 (31) | 1 (8) | 0.04* |
| ii.Cytogenetic response | |||||
| Major (MCyR) | 71 (75) | 24 (34) | 46 (65) | 1 (1) | 0.08 |
| Minor (mCyR) | 15 (16) | 6 (40) | 9 (60) | - | 0.90 |
| Poor (pCyR) | 9 (9) | 7 (78) | 2 (22) | - | 0.02* |
AA; Wild genotype, AG; Heterozygous genoype, GG; Homozygous variant genotype, MHR; Major hematological response, mHR; Minor hematological response, PHR; Poor hematological response, MCyR; Major cytogenetic response, mCyR; Minor cytogenetic response, pCyR; Poor cytogenetic response and *; Indicates statistically significant (P<0.05).